{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:44:58Z","timestamp":1785861898933,"version":"3.56.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1097\/01.cad.0000217426.82702.74","type":"journal-article","created":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T13:40:43Z","timestamp":1154439643000},"page":"859-864","source":"Crossref","is-referenced-by-count":33,"title":["Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin"],"prefix":"10.1097","volume":"17","author":[{"given":"Alexandra","family":"Wagner-Bohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao Paolo","family":"Vieira Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Gerss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Stoffregen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11912-005-0072-3","article-title":"Chemotherapy for advanced pancreatic cancer: past, present, and future","volume":"7","author":"Friberg G Kindler","year":"2005","journal-title":"Curr Oncol Rep"},{"key":"R2-14-20210203","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"R3-14-20210203","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00002820-199904000-00011","article-title":"Gemcitabine: a pharmacologic and clinical overview","volume":"22","author":"Barton-Burke","year":"1999","journal-title":"Cancer Nurs"},{"key":"R4-14-20210203","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1470-2045(05)01770-5","article-title":"Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas","volume":"6","author":"Maffuz","year":"2005","journal-title":"Lancet Oncol"},{"key":"R5-14-20210203","first-page":"37","article-title":"Integrating gemcitabine into breast cancer therapy","volume":"18","author":"Yardley","year":"2004","journal-title":"Oncology (Huntington)"},{"key":"R6-14-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.seminoncol.2003.12.017","article-title":"State-of-the-art chemotherapy for advanced non-small cell lung cancer","volume":"31","author":"Ramalingam","year":"2004","journal-title":"Semin Oncol"},{"key":"R7-14-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1040-8428(03)00119-7","article-title":"Gemcitabine: current role and future options in the treatment of ovarian cancer","volume":"48","author":"Fruscella","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"R8-14-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(03)01168-9","article-title":"The systemic treatment of advanced and metastatic bladder cancer","volume":"4","author":"Hussain","year":"2003","journal-title":"Lancet Oncol"},{"key":"R9-14-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1999.17.2.509","article-title":"Phase II trial of gemcitabine in refractory germ cell tumors","volume":"17","author":"Einhorn","year":"1999","journal-title":"J Clin Oncol"},{"key":"R10-14-20210203","first-page":"619","article-title":"Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma","volume":"24","author":"Ma","year":"2002","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R11-14-20210203","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3816\/CLM.2002.n.015","article-title":"Gemcitabine and its combinations in the treatment of malignant lymphoma","volume":"3","author":"Chau","year":"2002","journal-title":"Clin Lymphoma"},{"key":"R12-14-20210203","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.1994.12.8.1527","article-title":"Gemcitabine: current status of phase I and II trials","volume":"12","author":"Kaye","year":"1994","journal-title":"J Clin Oncol"},{"key":"R13-14-20210203","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1200\/JCO.1997.15.4.1697","article-title":"Methodologic issues in effectiveness research on palliative cancer care: a systematic review","volume":"15","author":"Rinck","year":"1997","journal-title":"J Clin Oncol"},{"key":"R14-14-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1191\/026921699668963873","article-title":"Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial","volume":"13","author":"Jordhoy","year":"1999","journal-title":"Palliat Med"},{"key":"R15-14-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1191\/0269216303pm785oa","article-title":"Attitudes of patients and staff to research in a specialist palliative care unit","volume":"17","author":"Ross C Cornbleet","year":"2003","journal-title":"Palliat Med"},{"key":"R16-14-20210203","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jpainsymman.2004.12.001","article-title":"The willingness of palliative care patients to participate in research","volume":"29","author":"Henderson","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"R17-14-20210203","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00043426-199705000-00002","article-title":"Pediatric phase II cancer chemotherapy trials: a Pediatric Oncology Group study","volume":"19","author":"Weitman","year":"1997","journal-title":"J Pediatr Hematol Oncol"},{"key":"R18-14-20210203","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/mpo.2950190417","article-title":"The conduct of phase I\u2013II clinical trials in children with cancer","volume":"19","author":"Pratt","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"R19-14-20210203","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1080\/1042819021000015880","article-title":"Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group","volume":"43","author":"Steinherz","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R20-14-20210203","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2004.10.142","article-title":"Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors","volume":"22","author":"Reid","year":"2004","journal-title":"J Clin Oncol"},{"key":"R21-14-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","article-title":"Response evaluation criteria in solid tumors (RECIST): new guidelines","volume":"37","author":"Tsuchida","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R22-14-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"R23-14-20210203","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R24-14-20210203","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/pbc.20419","article-title":"Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report","volume":"46","author":"Angiolillo","year":"2006","journal-title":"Pediatr Blood Cancer"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001813-200608000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:44:47Z","timestamp":1785858287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200608000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cad.0000217426.82702.74","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}